Last reviewed · How we verify
Placebo for Bexagliflozin
Placebo does not have a known mechanism of action.
Placebo does not have a known mechanism of action. Used for Type 2 diabetes.
At a glance
| Generic name | Placebo for Bexagliflozin |
|---|---|
| Sponsor | Theracos |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Type 2 diabetes
Common side effects
- Injection site reaction
- Nausea
- Headache
Key clinical trials
- Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study (PHASE4)
- An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension (PHASE2, PHASE3)
- Bexagliflozin Efficacy and Safety Trial (PHASE3)
- Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment (PHASE3)
- A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus (PHASE2)
- Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes (PHASE3)
- Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Bexagliflozin CI brief — competitive landscape report
- Placebo for Bexagliflozin updates RSS · CI watch RSS
- Theracos portfolio CI